Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Investig Arterioscler. 2017 Sep 18. pii: S0214-9168(17)30085-2. doi: 10.1016/j.arteri.2017.06.002. [Epub ahead of print]

Past, present and future of pharmacotherapy for obesity.

[Article in English, Spanish]

Author information

1
Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España. Electronic address: 96002@parcdesalutmar.cat.
2
Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España; Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, España.
3
Servicio de Endocrinología y Nutrición, Hospital del Mar de Barcelona, Barcelona, España.

Abstract

Conventional treatment for obesity with diet, exercise and bariatric surgery has limitations; thus, it is necessary to have pharmacological tools. In the past, different drugs were marketed that were withdrawn due to safety problems. There are currently 3 drugs approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for obesity therapy (orlistat, combination of bupropion and delayed-release naltrexone and liraglutide) and two more only authorized by FDA (lorcaserin and the combination of phentermine and extended release topiramate). It is recommended to use as a second therapeutic line and its choice should be individualized taking into account multiple aspects such as expected weight loss, route of administration, safety profile and cost. Currently there are several drugs under development that act on different therapeutic targets.

KEYWORDS:

Drug treatment; Exceso de peso; Farmacoterapia; Obesidad; Obesity; Overweight; Pharmacotherapy; Pérdida de peso; Tratamiento con fármacos; Weight loss

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center